The administration of argenx SE's modified antibody fragment, efgartigimod (ARGX-113), as four weekly doses on top of the usual standard of care of corticosteroids and immunomodulators, has been associated with a clinically meaningful and significant improvement in MG-ADL scores in a Phase II clinical study in 24 patients with generalized myasthenia gravis.
The Phase II study "catapults ARGX-113 forward on its timeline to Phase III clinical trials," company CEO Tim Van Hauwermeiren...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://insights.citeline.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)